Delgocitinib cream reduces itch and pain in adults with moderate to severe chronic hand eczema: pooled analyses of the Phase 3 DELTA-1 and -2 trials

Andrea Bauer¹, Marie-Louise Schuttelaar², Keith Baranowski³, Ursula Plohberger³, Laura Sørensen³, Margitta Worm⁴

¹Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany; ²University Medical Centre Groningen, University of Groningen, The Netherlands; ³LEO Pharma A/S, Ballerup, Denmark; ⁴Division of Allergy and Immunology, Department of Dermatology, Venerology and Allergy, Charité Universitätsmedizin Berlin, Germany

Introduction/Background: Itch and pain are two of the most common and burdensome symptoms of Chronic Hand Eczema. Delgocitinib cream, a topical pan-Janus kinase inhibitor, was well tolerated and demonstrated significant improvement in primary and all secondary efficacy endpoints in DELTA-1 (NCT04871711) and DELTA-2 (NCT04872101).

Objectives: The objectives of this analysis were to assess the effect on itch and pain of twice-daily applications of delgocitinib cream 20 mg/g, including early onset of reductions, compared with cream vehicle in the treatment of adults with moderate to severe CHE in a pooled analysis of the pivotal Phase 3 DELTA-1 and DELTA-2 trials.

Methods: This analysis includes pooled data from DELTA-1 and -2 (delgocitinib cream 20 mg/g [n=639]; cream vehicle [n=321]; twice-daily). The Hand Eczema Symptom
eDiary (HESD) captured patient-reported worst severity of itch and pain over the past 24 hours on an 11-point numeric rating scale (0=no itch/pain to 10=severe itch/pain). Changes in itch and pain from baseline were assessed daily during Week (W)1 and weekly from W1-16.

**Results:** For itch, a significant least square (LS) mean reduction from baseline was detected 1 day after patients first applied delgocitinib 20 mg/g (0.75) versus the cream vehicle group (0.32, P<0.001). For pain, a significant LS mean reduction was detected 3 days after the first application of delgocitinib cream (0.98) versus cream vehicle (0.58, P<0.001). The LS mean itch and pain reductions continued for delgocitinib cream-treated patients up to W16 (P<0.001). A clinically meaningful ≥4-point reduction in itch was achieved by significantly more patients applying delgocitinib cream from W2 (14.2%) versus cream vehicle (6.3%, P<0.001) and onwards to W16 (delgocitinib cream: 47.2%; cream vehicle: 21.5%; P<0.001). Similar results for a ≥4-point reduction in pain were observed.

**Conclusions:** Early onset of itch and pain reduction was observed within W1 for delgocitinib-treated patients, with reductions remaining significantly greater versus cream vehicle-treated patients from W1 to W16.

**Keywords:** chronic hand eczema, delgocitinib, JAK
Acknowledgements and Funding Sources: This analysis and medical writing support from Alphabet Health (New York, NY), by Michelle Dookwah-Smith, PhD, was funded by LEO Pharma A/S. This work was previously presented at AAD 2024, San Diego, CA, March 8-12, 2024.

Disclosures:

AB has been a speaker/advisor/investigator and/or received research funding from AbbVie, Almirall, Amgen, AstraZeneca, Biofrontera, Blueberry Therapeutics, Celldex, Centogene, Galderma, Genentech, Gilead, Incyte, LEO Pharma, Lilly, L’Oréal, Novartis, Sanofi, Regeneron, and Takeda.

MLS has been a consultant, advisory board member, investigator, and/or speaker for AbbVie, Amgen, Eli Lilly, Galderma, LEO Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme.

KB, LS, UP are employees of LEO Pharma A/S.

MW reports grants and personal fees from Stallergens, HAL Allergie, Bencard Allergie, Allergopharma, ALK-Abello, Mylan Germany, Actelion Pharmaceuticals Deutschland, Biotest, AbbVie Deutschland, Lilly Deutschland Aimmune, DBV Technologies, Regeneron Pharmaceuticals, Sanofi Aventis, Leo Pharma, Novartis, and Viatris, outside the submitted work and is past WAO co-chair of the anaphylaxis committee.